1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Multiple Sclerosis - Pipeline Review, H1 2020, provides an overview of the Multiple Sclerosis (Central Nervous System) pipeline landscape.
Multiple sclerosis (MS) is a potentially debilitating disease in which body's immune system eats away at the protective sheath (myelin) that covers nerves. Damage to myelin causes interference in the communication between brain, spinal cord and other areas of body. Symptoms include numbness or weakness in one or more limbs, double vision or blurring of vision, tingling or pain in parts of body, fatigue and slurred speech. The predisposing factors include age, gender, family history and certain infections.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Multiple Sclerosis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Multiple Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Multiple Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Multiple Sclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 1, 14, 21, 41, 2, 195, 38 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 2 and 40 molecules, respectively.
Multiple Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple Sclerosis (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Multiple Sclerosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Multiple Sclerosis (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Multiple Sclerosis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Multiple Sclerosis (Central Nervous System)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Multiple Sclerosis (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Multiple Sclerosis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Multiple Sclerosis - Overview
- Multiple Sclerosis - Therapeutics Development
- Multiple Sclerosis - Therapeutics Assessment
- Multiple Sclerosis - Companies Involved in Therapeutics Development
- Multiple Sclerosis - Drug Profiles
- Multiple Sclerosis - Dormant Projects
- Multiple Sclerosis - Discontinued Products
- Multiple Sclerosis - Product Development Milestones
- Appendix
List of Tables
- Number of Products under Development for Multiple Sclerosis, H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Products under Development by Companies, H1 2020
- Products under Development by Universities/Institutes, H1 2020
- Number of Products by Stage and Target, H1 2020
- Number of Products by Stage and Mechanism of Action, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
- Multiple Sclerosis - Pipeline by 4D Pharma Plc, H1 2020
- Multiple Sclerosis - Pipeline by AB Science SA, H1 2020
- Multiple Sclerosis - Pipeline by AbbVie Inc, H1 2020
- Multiple Sclerosis - Pipeline by Abeome Corp, H1 2020
- Multiple Sclerosis - Pipeline by Abion Inc, H1 2020
- Multiple Sclerosis - Pipeline by Abivax SA, H1 2020
- Multiple Sclerosis - Pipeline by Abreos Biosciences Inc, H1 2020
- Multiple Sclerosis - Pipeline by Accure Therapeutics SL, H1 2020
- Multiple Sclerosis - Pipeline by Acelerox LLC, H1 2020
- Multiple Sclerosis - Pipeline by Actelion Pharmaceuticals Ltd, H1 2020
- Multiple Sclerosis - Pipeline by Aequus Pharmaceuticals Inc, H1 2020
- Multiple Sclerosis - Pipeline by Affectis Pharmaceuticals AG, H1 2020
- Multiple Sclerosis - Pipeline by AgoneX Biopharmaceuticals Inc, H1 2020
- Multiple Sclerosis - Pipeline by Ahead Therapeutics SL, H1 2020
- Multiple Sclerosis - Pipeline by Akaal Pharma Pty Ltd, H1 2020
- Multiple Sclerosis - Pipeline by Alexion Pharmaceuticals Inc, H1 2020
- Multiple Sclerosis - Pipeline by Alpha Cancer Technologies Inc, H1 2020
- Multiple Sclerosis - Pipeline by Alpine Immune Sciences Inc, H1 2020
- Multiple Sclerosis - Pipeline by Altheia Science SRL, H1 2020
- Multiple Sclerosis - Pipeline by Amgen Inc, H1 2020
- Multiple Sclerosis - Pipeline by Anavex Life Sciences Corp, H1 2020
- Multiple Sclerosis - Pipeline by Ankar Pharma SL, H1 2020Multiple Sclerosis - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
- Multiple Sclerosis - Pipeline by Teikoku Pharma USA Inc, H1 2020
- Multiple Sclerosis - Pipeline by Tellus Therapeutics Inc, H1 2020
- Multiple Sclerosis - Pipeline by TeraImmune Inc, H1 2020
- Multiple Sclerosis - Pipeline by Tetra Therapeutics, H1 2020
- Multiple Sclerosis - Pipeline by Theratome Bio Inc, H1 2020
- Multiple Sclerosis - Pipeline by Therini Bio Inc, H1 2020
- Multiple Sclerosis - Pipeline by Tiziana Life Sciences Plc, H1 2020
- Multiple Sclerosis - Pipeline by Toleranzia AB, H1 2020
- Multiple Sclerosis - Pipeline by TolerogenixX GmbH, H1 2020
- Multiple Sclerosis - Pipeline by Tonix Pharmaceuticals Holding Corp, H1 2020
- Multiple Sclerosis - Pipeline by Topas Therapeutics GmbH, H1 2020
- Multiple Sclerosis - Pipeline by Transparency Life Sciences LLC, H1 2020
- Multiple Sclerosis - Pipeline by Trio Medicines Ltd, H1 2020
- Multiple Sclerosis - Pipeline by TwotoBiotech Ltd, H1 2020
- Multiple Sclerosis - Pipeline by UBI Pharma Inc, H1 2020
- Multiple Sclerosis - Pipeline by V Clinbio LLC, H1 2020
- Multiple Sclerosis - Pipeline by Vaccinex Inc, H1 2020
- Multiple Sclerosis - Pipeline by Vascular Biogenics Ltd, H1 2020
- Multiple Sclerosis - Pipeline by Vertex Pharmaceuticals Inc, H1 2020
- Multiple Sclerosis - Pipeline by Virogenomics BioDevelopment Inc, H1 2020
- Multiple Sclerosis - Pipeline by Virtici LLC, H1 2020
- Multiple Sclerosis - Pipeline by Vitalis LLC, H1 2020
- Multiple Sclerosis - Pipeline by Vitality Biopharma Inc, H1 2020
- Multiple Sclerosis - Pipeline by Xalud Therapeutics Inc, H1 2020
- Multiple Sclerosis - Pipeline by Xonovo Inc, H1 2020
- Multiple Sclerosis - Pipeline by ZyVersa Therapeutics Inc, H1 2020
- Multiple Sclerosis - Dormant Projects, H1 2020
- Multiple Sclerosis - Discontinued Products, H1 2020
- Multiple Sclerosis - Discontinued Products, H1 2020 (Contd..1), H1 2020
- Multiple Sclerosis - Discontinued Products, H1 2020 (Contd..2), H1 2020
List of Figures
- Number of Products under Development for Multiple Sclerosis, H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Number of Products by Top 10 Targets, H1 2020
- Number of Products by Stage and Top 10 Targets, H1 2020
- Number of Products by Top 10 Mechanism of Actions, H1 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
- Number of Products by Top 10 Routes of Administration, H1 2020
- Number of Products by Stage and Top 10 Routes of Administration, H1 2020
- Number of Products by Top 10 Molecule Types, H1 2020
- Number of Products by Stage and Top 10 Molecule Types, H1 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 4D Pharma Plc
- AB Science SA
- AbbVie Inc
- Abeome Corp
- Abion Inc
- Abivax SA
- Abreos Biosciences Inc
- Accure Therapeutics SL
- Acelerox LLC
- Actelion Pharmaceuticals Ltd
- Aequus Pharmaceuticals Inc
- Affectis Pharmaceuticals AG
- AgoneX Biopharmaceuticals Inc
- Ahead Therapeutics SL
- Akaal Pharma Pty Ltd
- Alexion Pharmaceuticals Inc
- Alpha Cancer Technologies Inc
- Alpine Immune Sciences Inc
- Altheia Science SRL
- Amgen Inc
- Anavex Life Sciences Corp
- Ankar Pharma SL
- Anokion SA
- Antisense Therapeutics Ltd
- AnTolRx Inc
- Anvyl LLC
- Apaxen
- Aphios Corp
- Apimeds Inc
- Apitope International NV
- Aprilbio Co Ltd
- Artax Biopharma Inc
- Asdera LLC
- AstraZeneca Plc
- Atara Biotherapeutics Inc
- Athersys Inc
- Athira Pharma Inc
- Atlantic Bio Sci LLC
- Autobahn Therapeutics Inc
- Autoimmunity Biologic Solutions Inc
- Avicanna Inc
- Axial Biotherapeutics Inc
- Axxam SpA
- Barricade Therapeutics Corp
- Bayer AG
- Baylx Inc
- BioAegis Therapeutics Inc
- BioApex sro
- Biocad
- Biocon Ltd
- Biocure Technology Inc
- Biogen Inc
- BioIncept LLC
- Biond Biologics Ltd
- Biovista Inc
- Bolder Biotechnology Inc
- Boston Pharmaceuticals Inc
- BrainStorm Cell Therapeutics Inc
- Bridge Biotherapeutics Inc
- Bristol-Myers Squibb Co
- BTB Pharma AB
- Califia Bio Inc
- Cardinal Therapeutics Inc
- CavoGene LifeSciences
- Cerion LLC
- CGeneTech (Suzhou China) Co Ltd
- Chipscreen Biosciences Ltd
- Cinnagen Co
- Clene Nanomedicine Inc
- Coherus BioSciences Inc
- Commence Bio Inc
- Complement Pharma BV
- Compugen Ltd
- Convelo Therapeutics Inc
- Corium, Inc.
- Cour Pharmaceuticals Development Co Inc
- Curadim Pharma Co Ltd
- CuraVac Inc
- CuroNZ Ltd
- Curyx Bio Inc
- Cyteir Therapeutics Inc
- Cytocom Inc
- Cytodyn Inc
- Cyxone AB
- DC4U BV
- Denali Therapeutics Inc
- DiNonA Inc
- Disarm Therapeutics Inc
- Dr. Reddy's Laboratories Ltd
- Druggability Technologies Holdings Ltd
- Dualogics Corp
- EA Pharma Co Ltd
- Eldrug SA
- Eli Lilly and Co
- Emerald Health Sciences Inc
- Endece LLC
- EnhanX Biopharm Inc
- Enterin Inc
- Epitracker Inc
- Eton Pharmaceuticals Inc
- Evgen Pharma Plc
- F. Hoffmann-La Roche Ltd
- Farmacija d.o.o. Tuzla
- FibroGenesis LLC
- Fortuna Fix Inc
- Frequency Therapeutics Inc
- GABA Therapeutics Inc
- Gemac SA
- Genervon Biopharmaceuticals LLC
- GeNeuro SA
- Gilead Sciences Inc
- GlaxoSmithKline Plc
- Glialogix Inc
- Glixis Therapeutics LLC
- Glixogen Therapeutics
- Handa Pharmaceuticals LLC
- Humabs BioMed SA
- HuniLife Biotechnology Inc
- Hutchison MediPharma Ltd
- IL-2Rx Inc
- Iltoo Pharma
- ImCyse SA
- Immune Response BioPharma Inc
- Immungenetics AG
- Immunic Inc
- Immunwork Inc
- ImmusanT Inc
- Immutep Ltd
- Impetis Biosciences Ltd
- Imstem Biotechnology Inc
- Inflazome Ltd
- Inmune Bio Inc
- InnoBioscience LLC
- Innovimmune Biotherapeutics Inc
- InSight Biopharmaceuticals Ltd
- Io Therapeutics Inc
- Istesso Ltd
- J2H Biotech
- Jura Bio Inc
- Jyant Technologies Inc
- Karo Pharma AB
- Klogene Therapeutics Inc
- Kogenix Therapeutics Inc
- Kyorin Pharmaceutical Co Ltd
- Landos Biopharma Inc
- Lead Discovery Center GmbH
- Leukosight Inc
- LFB SA
- LIFNano Rx Ltd
- Llama Therapeutics Inc
- Mabion SA
- MAKScientific LLC
- Mapi Pharma Ltd
- Maruho Co Ltd
- Med-Life Discoveries LP
- MedAnnex Ltd
- MedDay SA
- Medicenna Therapeutics Corp
- Merck KGaA
- Meta-IQ ApS
- MetiMedi Pharmaceuticals Co Ltd
- MetrioPharm AG
- Millennium Pharmaceuticals Inc
- Mirae Cell Bio Co Ltd
- Mitochon Pharmaceuticals Inc
- Mitotech SA
- Mitsubishi Tanabe Pharma Corp
- MMJ International Holdings Corp
- Mochida Pharmaceutical Co Ltd
- Molecules For Health Inc
- MorphoSys AG
- Mount Tam Biotechnologies Inc
- MyMD Pharmaceuticals Inc
- NervGen Pharma Corp
- Neuren Pharmaceuticals Ltd
- Neuro Vigor LLC
- Neurodegeneration Therapeutics Inc
- Neurotrope Bioscience Inc
- New World Laboratories Inc
- Novartis AG
- Novoron Bioscience Inc
- Numab Therapeutics AG
- Omeros Corp
- Oncodesign SA
- OncoImmune Inc
- Op-T-Mune Inc
- Orion Biotechnology Canada Ltd
- Orpheris Inc
- Oryzon Genomics SA
- Oscine Therapeutics
- OSE Immunotherapeutics
- Ossianix Inc
- Pahan Therapeutics
- Pangen Biotech Inc
- Par'Immune SAS
- Parkside Scientific Inc
- PharmatrophiX Inc
- PharmCADD Co Ltd
- Pheno Therapeutics Ltd
- Pipeline Therapeutics Inc
- Polpharma Biologics
- PolTREG Sp z o o
- Principia Biopharma Inc
- Progenitor Therapeutics Ltd
- Promethera Biosciences SA
- ProNoxis AB
- Proteorex Therapeutics Inc
- Provid Pharmaceuticals Inc
- Q Therapeutics Inc
- Quimatryx SL
- Reata Pharmaceuticals Inc
- ReceptoPharm Inc
- RedHill Biopharma Ltd
- RegeneRx Biopharmaceuticals Inc
- RemeGen Ltd
- ReNeuroGen LLC
- Renovo Neural Inc
- Resverlogix Corp
- Revalesio Corp
- Reven Pharmaceuticals Inc
- ReveraGen BioPharma Inc
- Rewind Therapeutics NV
- Rhizen Pharmaceuticals SA
- Rigel Pharmaceuticals Inc
- Riptide Bioscience Inc
- Rodos BioTarget GmbH
- Rubius Therapeutics Inc
- SanBio Company Limited
- Sangamo Therapeutics Inc
- Sanofi
- Sansho Co Ltd
- Sarepta Therapeutics Inc
- Sareum Holdings Plc
- Scientus Pharma Inc
- Seneca Biopharma Inc
- Senju Pharmaceutical Co Ltd
- Senzer Ltd
- SK Chemicals Co Ltd
- Stem Cell Medicine Ltd
- Sujana Biotech, LLC
- Suzhou Connect Biopharmaceuticals Ltd
- Symbiotix Biotherapies Inc
- SynAct Pharma AB
- Takeda Pharmaceutical Co Ltd
- Teikoku Pharma USA Inc
- Tellus Therapeutics Inc
- TeraImmune Inc
- Tetra Therapeutics
- Theratome Bio Inc
- Therini Bio Inc
- Tiziana Life Sciences Plc
- Toleranzia AB
- TolerogenixX GmbH
- Tonix Pharmaceuticals Holding Corp
- Topas Therapeutics GmbH
- Transparency Life Sciences LLC
- Trio Medicines Ltd
- TwotoBiotech Ltd
- UBI Pharma Inc
- V Clinbio LLC
- Vaccinex Inc
- Vascular Biogenics Ltd
- Vertex Pharmaceuticals Inc
- Virogenomics BioDevelopment Inc
- Virtici LLC
- Vitalis LLC
- Vitality Biopharma Inc
- Xalud Therapeutics Inc
- Xonovo Inc
- ZyVersa Therapeutics Inc
